Visits: 1818, Avg visit time (secs): 249,77 Back to Index
| Page | Hits | Percent |
|---|---|---|
| 1134 | 62,38% | |
| /programmes.html | 101 | 5,56% |
| /msd/basic/efsd-msd-basic-rfa09.html | 75 | 4,13% |
| /dcure/efsd-dcure-rfa08.html | 51 | 2,81% |
| /novartis/efsd-novartis-rfa09.html | 34 | 1,87% |
| /msd/clinical/efsd-msd-clinical-rfa09.html | 31 | 1,71% |
| /regulations.html | 30 | 1,65% |
| /new_horizons/new-horizons09.html | 27 | 1,49% |
| /msd/albert-renold/efsd-msd-arenold.html | 23 | 1,27% |
| /home.html | 22 | 1,21% |
| /amylin/efsd-amylin-rfa09.html | 19 | 1,05% |
| Page | Hits | Percent |
|---|---|---|
| /exit.htm | 1150 | 63,26% |
| /new_horizons/new-horizons09.html | 145 | 7,98% |
| /dcure/efsd-dcure-rfa08.html | 51 | 2,81% |
| /home.html | 34 | 1,87% |
| /lilly/fellowships/efsd-lilly-fship09.html | 32 | 1,76% |
| /programmes.html | 31 | 1,71% |
| /efsd-grant/efsd-clinresgrant-rfa08.html | 26 | 1,43% |
| /msd/basic/efsd-msd-basic-rfa09.html | 20 | 1,10% |
| /recipients.html | 16 | 0,88% |
| /gsk/efsd-gsk-rfa08.html | 16 | 0,88% |
| /msd/clinical/efsd-msd-clinical-rfa09.html | 16 | 0,88% |